Biogen Inc. $BIIB Shares Sold by China Universal Asset Management Co. Ltd.

Key Points

• China Universal Asset Management cut its stake in Biogen by 19.2%, selling 5,665 shares and leaving it with 23,905 shares worth about $4.21 million per its latest SEC filing.
• Biogen beat Q4 estimates with $1.99 EPS (consensus $1.61) and $2.28B revenue (consensus $2.21B) but revenue was down 7.2% year‑over‑year; the company issued FY‑2026 EPS guidance of 15.25–16.25.
• Analysts are split: some firms raised targets or upgraded (e.g., Oppenheimer to $275, UBS to Buy at $225) while others remain cautious (HSBC Reduce at $150), leaving an average target near $211 and a consensus rating of Hold.

China Universal Asset Management Co. Ltd. lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,905 shares of the biotechnology company's stock after selling 5,665 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Biogen were worth $4,207,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. WPG Advisers LLC increased its position in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC increased its position in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 185 shares in the last quarter. First Horizon Corp acquired a new stake in Biogen during the 4th quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in Biogen during the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC increased its position in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 90 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Stock Performance

Biogen stock opened at $187.88 on Friday. The company has a market cap of $27.57 billion, a PE ratio of 21.33, a P/E/G ratio of 2.54 and a beta of 0.16. The company has a fifty day moving average price of $185.37 and a two-hundred day moving average price of $174.82. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen Inc. has a 12 month low of $115.25 and a 12 month high of $202.41.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts' consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm's revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts expect that Biogen Inc. will post 15.75 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on BIIB shares. Sanford C. Bernstein reissued a "market perform" rating on shares of Biogen in a research report on Monday, February 9th. JPMorgan Chase & Co. increased their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a "neutral" rating in a research report on Thursday. Barclays initiated coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an "equal weight" rating and a $185.00 price objective for the company. Oppenheimer increased their price objective on shares of Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research report on Wednesday, April 1st. Finally, Wolfe Research set a $231.00 price objective on shares of Biogen in a research report on Monday, February 9th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $211.31.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a “slew of pipeline catalysts” over the next 12–15 months that could materially boost revenue and valuation. Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Neutral Sentiment: Several analysts issued mixed takes — some raising targets but keeping neutral ratings, which suggests upside is acknowledged but not consensus conviction. This readjusts expectations without flipping broad buy/sell positioning. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB)...
• Neutral Sentiment: JPMorgan raised its price target to $185 but kept a Neutral rating — marginally higher valuation support but still limited upside per their view. MarketScreener: JPMorgan adjusts price target on Biogen to $185
• Neutral Sentiment: Rothschild & Co Redburn raised its target to $180 but kept a Neutral rating — another example of price‑target lift without a buy endorsement. MarketScreener: Rothschild & Co Redburn adjusts Biogen price target to $180
• Neutral Sentiment: Jim Cramer noted he’s “reopening the file” on Biogen after recent coverage and upgrades — a media boost that can support short‑term interest but isn’t an analyst endorsement. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Negative Sentiment: Wolfe Research trimmed its Q1 2026 EPS estimate (from $2.79 to $2.64) even as it nudged FY‑2027 estimates higher — the near‑term cut can pressure the stock ahead of earnings.
• Negative Sentiment: HSBC reiterated a Reduce rating and uses a $150 target — a markedly lower anchor than UBS and others, which can prompt selling by investors who follow conservative sell‑side views. What is HSBC's Estimate for Biogen Q1 Earnings?
• Neutral Sentiment: Barclays reaffirmed its Hold rating — another stabilizing but non‑bullish stance. Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.